{
    "ticker": "BMEA",
    "name": "Biomea Fusion, Inc.",
    "description": "Biomea Fusion, Inc. is a biotechnology company focused on developing innovative therapies for patients with genetically defined cancers. Founded in 2020 and headquartered in Boulder, Colorado, Biomea is dedicated to advancing precision medicine through the discovery and development of small molecule therapies that target specific genetic mutations. The company's proprietary platform integrates advanced computational biology and medicinal chemistry to identify and optimize candidates for clinical development. Biomea's lead drug candidate, BMF-219, is designed to treat patients with KRAS G12C mutations, a prevalent driver of multiple cancers. The company aims to provide transformative treatment options for patients who have limited alternatives, thereby improving outcomes and quality of life. Biomea is committed to transparency and collaboration within the scientific community, striving to contribute to the broader understanding of cancer biology and therapeutic approaches. With a strong pipeline and promising initial clinical results, Biomea is well-positioned to make a significant impact in the oncology field.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Boulder, Colorado, USA",
    "founded": "2020",
    "website": "https://www.biomeafusion.com",
    "ceo": "Thomas Butler",
    "social_media": {
        "twitter": "https://twitter.com/BiomeaFusion",
        "linkedin": "https://www.linkedin.com/company/biomea-fusion/"
    },
    "investor_relations": "https://www.biomeafusion.com/investors",
    "key_executives": [
        {
            "name": "Thomas Butler",
            "position": "CEO"
        },
        {
            "name": "Scott Smith",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Therapies",
            "products": [
                "BMF-219"
            ]
        }
    ],
    "seo": {
        "meta_title": "Biomea Fusion, Inc. | Precision Oncology and Biotechnology",
        "meta_description": "Explore Biomea Fusion, Inc., a biotech company dedicated to developing innovative cancer therapies. Learn about our mission in precision medicine and our lead candidate BMF-219.",
        "keywords": [
            "Biomea Fusion",
            "Biotechnology",
            "Oncology",
            "Cancer Treatment",
            "Precision Medicine",
            "BMF-219"
        ]
    },
    "faq": [
        {
            "question": "What is Biomea Fusion known for?",
            "answer": "Biomea Fusion is known for developing precision therapies for genetically defined cancers."
        },
        {
            "question": "Who is the CEO of Biomea Fusion?",
            "answer": "Thomas Butler is the CEO of Biomea Fusion, Inc."
        },
        {
            "question": "Where is Biomea Fusion headquartered?",
            "answer": "Biomea Fusion is headquartered in Boulder, Colorado, USA."
        },
        {
            "question": "What is Biomea's lead product?",
            "answer": "Biomea's lead product is BMF-219, targeting KRAS G12C mutations."
        },
        {
            "question": "When was Biomea Fusion founded?",
            "answer": "Biomea Fusion was founded in 2020."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "MRNA",
        "NVTA"
    ],
    "related_stocks": [
        "GILD",
        "ABBV",
        "VRTX",
        "BMY"
    ]
}